Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report

Immune checkpoint inhibitors (ICIs) are extensively utilized in the treatment of oncological patients, and the immune-related adverse reactions they induce merit close monitoring. This report describes a case of a lung cancer patient who, after receiving chemotherapy in combination with the programm...

Full description

Bibliographic Details
Published in:	Frontiers in Immunology
Main Authors:	Ming-xing Wang, Ai-xin Liu, Qing-ming Sun, Wan-hui Dong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Subjects:	sintilimab hypophysitis diabetes insipidus adverse reactions immune checkpoint inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534179/full

Similar Items

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis
by: LI Jia-yi, XING Bing
Published: (2020-03-01)

Patterns of hormonal changes in hypophysitis by immune checkpoint inhibitor
by: Hyunji Sang, et al.
Published: (2024-09-01)

Analysis of the clinical characteristics of immune checkpoint inhibitor-related hypophysitis
by: Zhixiao WANG, et al.
Published: (2025-08-01)

Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience
by: Narin Nasiroglu Imga, et al.

Immune checkpoint inhibitor induced hypophysitis: a specific disease of corticotrophs?
by: Nishchil Patel, et al.
Published: (2024-10-01)

Clinical Characteristics, Management, and Outcome of 22 Cases of Primary Hypophysitis
by: Sun Mi Park, et al.
Published: (2014-12-01)

Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:  A Case Report and Literature Review
by: Jingjing CAI, et al.
Published: (2023-09-01)

Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review
by: Shuting Zhou, et al.
Published: (2023-12-01)

Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment
by: Baohui Hong, et al.
Published: (2024-02-01)

Case Report: Dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies
by: Bin Shan, et al.
Published: (2025-10-01)

High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial
by: Verena Theiler-Schwetz, et al.
Published: (2025-12-01)

A Predictive Score Incorporating Clinical, Radiologic, and Hormonal Parameters to Discriminate Lymphocytic Hypophysitis from Non-Functioning Pituitary Macroadenomas
by: Ach Taieb, et al.
Published: (2025-09-01)

Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors—A Single-Center Study
by: Anna Lea Amylidi, et al.
Published: (2023-12-01)

Hypophysitis with adrenal insufficiency secondary to immune checkpoint inhibitors therapy
by: Julián Barbosa Arana, et al.
Published: (2024-05-01)

Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer
by: Peipei Mou, et al.
Published: (2025-04-01)

Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report
by: Jiang Z, et al.
Published: (2023-11-01)

Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis
by: Stephanie van der Leij, et al.
Published: (2024-07-01)

Ischemic Pituitary Apoplexy, Hypopituitarism and Diabetes Insipidus: a Triad Unique to Necrotizing Hypophysitis
by: Miroslav Ćaćić, et al.
Published: (2018-01-01)

Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
by: Guo Hong, et al.
Published: (2023-10-01)

Refractory pruritus caused by sintilimab and its clinical management: A case report
by: Li Chen, et al.
Published: (2024-07-01)

Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report
by: Qian Hao, et al.
Published: (2025-07-01)

Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
by: Zichang Liu, et al.
Published: (2023-03-01)

Radiological and hormonal improvements in a 22-year-old patient with lymphocytic hypophysitis — the watchful waiting approach
by: Aleksandra Gilis-Januszewska, et al.
Published: (2020-02-01)

Clinical characteristic analysis of immune checkpoint inhibitor-related pituitary adverse events
by: Yufan ZHENG, et al.
Published: (2025-08-01)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
by: Le Zhang, et al.
Published: (2023-03-01)

Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis
by: Anna Galligan, et al.
Published: (2023-11-01)

Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature
by: Jiaxiang Ji, et al.
Published: (2024-12-01)

Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists
by: Irena Druce, et al.
Published: (2022-07-01)

Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review
by: Lei Wang, et al.
Published: (2024-04-01)

Progress in Diagnosis and Treatment of Autoimmune Hypophysitis
by: ZHAI Xiao, et al.
Published: (2022-01-01)

Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
by: Jiang Chunyan, et al.
Published: (2023-06-01)

The Pituitary Immune Environment and Immunotherapy: From Hypophysitis to Pituitary Neuroendocrine Tumors
by: Toru Tateno, et al.
Published: (2025-09-01)

From Innovation to Complication: A Case Report and Review on Immune-Related Colitis Induced by ICIs
by: Huibo Li, et al.
Published: (2025-08-01)

Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review
by: Remya Rajan, et al.
Published: (2025-07-01)

Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population
by: Khor Zhong Wei, et al.
Published: (2019-03-01)

Successful treatment with sintilimab for SMARCA4-deficient non-small cell lung carcinoma: two case reports
by: Liwen Wang, et al.
Published: (2025-07-01)

Autoimmune GFAP astrocytopathy manifesting as sintilimab-induced myelitis: a Case Report and literature review
by: Xue Ma, et al.
Published: (2025-08-01)

Trastuzumab Deruxtecan for brain metastatic squamous lung carcinoma with immune-related hypophysitis: a case report
by: Rui Xu, et al.
Published: (2025-09-01)

PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer
by: Yan Jia, et al.
Published: (2024-10-01)

Case report: A rare case of anti-PD-1 sintilimab-induced agranulocytosis/severe neutropenia in non-small cell lung cancer and literature review
by: Yanzhu Qin, et al.
Published: (2024-06-01)